Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01447914 · OUTCOME

Duration of Response

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma · Source last updated 2019-08-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
From first observation of partial response to the time of disease progression, assessed up to 30 days

What was measured

Kaplan and Meier product limit methods will be used to estimate the DOR with 95% confidence intervals.

Analysis population: No participants responded to the therapy and no analyses were done

Groups in this outcome

Tivantinib Treatment

Oral Tivantinib 360 mg twice daily continuously for each day of every 28 day treatment cycle (taken as three tablets of 120 mg each)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Tivantinib Treatment0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
Kaplan and Meier product limit methods will be used to estimate the DOR with 95% confidence intervals.
groups
  1. description
    Oral Tivantinib 360 mg twice daily continuously for each day of every 28 day treatment cycle (taken as three tablets of 120 mg each)
    id
    OG000
    title
    Tivantinib Treatment
population Description
No participants responded to the therapy and no analyses were done
reporting Status
POSTED
time Frame
From first observation of partial response to the time of disease progression, assessed up to 30 days
title
Duration of Response
type
OTHER_PRE_SPECIFIED

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice